Abstract

Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application

Author(s): Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli

Issue: Sep/Oct 2021 - Volume 25, Number 5

Page(s): 422-426

Download in electronic PDF format for $75
  • Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Page 1
  • Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Page 2
  • Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Page 3
  • Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Page 4
  • Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application Page 5

Abstract

Transdermal products are intended to be applied topically but to promote the biological effects systemically, while transmucosal products have the same final effect but are to be applied on mucosa (for example, vaginal mucosa). The extension and velocity in which absorption occurs vary depending on the vehicle used, the active pharmaceutical ingredient and a broad range of other factors related to the formulation, patient, and environmental characteristics. Ready-to-use vehicles, such as Pentravan, with proven penetration efficacy for various active pharmaceutical ingredients, are paramount. Pentravan, specially developed for compounding pharmacies, has been extensively studied. To date, most studies have focused on endocrinology (e.g., sexual hormones), anti-aging strategies, and gynecology (endometriosis and related conditions). In this work, we have determined the compatibility of Pentravan and three active pharmaceutical ingredients: gestrinone, a steroidal substance for vaginal use (endometriosis), and nimesulide and piroxicam, two nonsteroidal anti-inflammatory drugs used both for topical and vaginal application. This article shows an excellent beyond-use date of 180 days when stored at room temperature, which renders it suitable for daily practice.

Related Keywords

  • gestrinone
  • nimesulide
  • piroxicam
  • steroid
  • nonsteroidal anti-inflammatory drugs
  • NSAIDs
  • compatibility
  • Pentravan
  • transdermal administration
  • transmucosal preparation
  • topical preparations
  • transdermal permeation
  • dermal penetration
  • vaginal administration
  • physical stability
  • chemical stability

Related Categories

  • GERIATRICS
  • PEER-REVIEWED
  • STABILITIES, COMPATIBILITIES
  • ALLERGY/IMMUNOLOGY/INFLAMMATION
  • DOSAGE FORMS/DRUG CARRIERS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2021
Pg. 422-426
Compatibility of Gestrinone, Nimesulide, and Piroxicam in Pentravan for Transdermal and Transmucosal Application
Author(s): Polonini Hudson, de Oliveira Ferreira Anderson, Dijkers Eli
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Mar/Apr 2004
Pg. 101-105
Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs
Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Jul/Aug 2014
Pg. 332-340
Evaluation of Percutaneous Absorption Performance for Human Female Sexual Steroids into Pentravan Cream
Author(s): Polonini Hudson C, Brandão Marcos Antônio F, Ferreira Anderson O, Ramos Cristiano, Raposo Nádia R B
Nov/Dec 1999
Pg. 496-500
Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations
Author(s): Goodwin Donald A, Fuhram L Clifton
Jan/Feb 2006
Pg. 14-18
View Sample
Transdermal Administration of Anti-inflammatory Medications in Sports Injuries: Use of Iontophoresis and Phonophoresis to Enhance Delivery
Author(s): Heim Bob
Jul/Aug 2002
Pg. 311-315
Compatibility Screening of Bivalirudin During Simulated Y-Site Administration with Other Drugs
Author(s): Trissel Lawrence A, Saenz Christopher
May/Jun 2013
Pg. 254-261
Physiochemical Compatibility of Nebulizable Drug Admixtures Containing Budesonide and Colistmethate or Hypertonic Saline
Author(s): Klemmer Anja, Krämer Irene, Kamin Wolfgang
May/Jun 2010
Pg. 204-206
Managing Pain with Transdermal Ketoprofen
Author(s): Williams KaCee D
Jan/Feb 2011
Pg. 69
Piroxicam 1% Gel
Author(s): Allen Loyd V Jr
Jan/Feb 2021
Pg. 52-61
Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration
Author(s): Lu Juan, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T
Sep/Oct 2006
Pg. 351
Case Report: Treatment of Migraines with Compounded Piroxicam Mini-Troches
Author(s): Williams Steve D
Jan/Feb 2008
Pg. 71
Piroxicam 1% Soft-Patch Lipophilic Gel
Author(s): Allen Loyd V Jr
Jan/Feb 2008
Pg. 72
Piroxicam 1% Soft-Patch Topical Gel
Author(s): Allen Loyd V Jr
Sep/Oct 2008
Pg. 454
Piroxicam 5% and Dexpanthenol 5% Gel
Author(s): Allen Loyd V Jr
May/Jun 2006
Pg. 230-233
Compatibility of Micafungin Injection with Other Drugs During Simulated Y-Site Co-administration
Author(s): Trusley Craig, Kupiec Thomas C, Trissel Lawrence A
Jan/Feb 2001
Pg. 69-73
Compatibility Screening of Hextend During Simulated Y-Site Administration with Other Drugs
Author(s): Trissel Lawrence A, Williams Kimberly Y, Baker Ma
Nov/Dec 2023
Pg. 494-502
Pathophysiology and Management of Onychomycosis and Novel Approaches for Effective Transdermal Applications
Author(s): Dharmian Jose Prakash, Sathiyaseelan Iraniammal, Renganathan Akshaya, Mubees Alamaan Mohamed, Naser Mohammed Yasin Abdul, Ramkrishnan Prakash, Arumugam Somasundaram
Mar/Apr 2024
Pg. 131
Amitriptyline Hydrochloride 2%, Carbamazepine 2%, Gabapentin 10%, and Ketoprofen 2% Transdermal Gel
Author(s): Allen Loyd V Jr
May/Jun 2007
Pg. 181-184
Transdermal Gel in the Treatment of Postoperative Pain
Author(s): Alexander Kayla, Wynn Tom